rafivirumab (99)

Structure	

Heavy chain / Chaone lourde / Cadena pesada

EVQLVQSGAE	VKKPGSSVKV	SCKASGGTFN	RYTVNWVRQA	PGQGLEWMGG	50

IIPIFGTANY	AQRFQGRLTI	TADESTSTAY	MELSSLRSDD	TAVYFCAREN	100

LDNSGTYYYF	SGWFDPWGQG	TLVTVSSAST	KGPSVFPLAP	SSKSTSGGTA	150

ALGCLVKDYF	PEPVTVSWNS	GALTSGVHTF	PAVLQSSGLY	SLSSVVTVPS	200

SSLGTQTYIC	NVNHKPSNTK	VDKRVEPKSC	DKTHTCPPCP	APELLGGPSV	250

FLFPPKPKDT	LMISRTPEVT	CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK	300

PREEQYNSTY	RVVSVLTVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTISKAK	350

GQPREPQVYT	LPPSREEMTK	NQVSLTCLVK	GFYPSDIAVE	WESNGQPENN	400

YKTTPPVLDS	DGSFFLYSKL	TVDKSRWQQG	NVFSCSVMHE	ALHNHYTQKS	450

LSLSPG



	456

Light chain / Chaone lygire / Cadena ligera

ESALTQPRSV	SGSPGQSVTI	SCTGTSSDIG	GYNFVSWYQQ	HPGKAPKLMI	50?

YDATKRPSGV	PDRFSGSKSG	NTASLTISGL	QAEDEADYYC	CSYAGDYTPG	100?

VVFGGGTKLT	VLGQPKAAPS	VTLFPPSSEE	LQANKATLVC	LISDFYPGAV	150?

TVAWKADSSP	VKAGVETTTP	SKQSNNKYAA	SSYLSLTPEQ	WKSHRSYSCQ	200?

VTHEGSTVEK	TVAPTECS



218?

Disulfide bridges location / Position des ponts disulfure / Posiciones
de los puentes disulfuro

22-96	22??-96??	22?-90?	22???-90???	140?-199?	140???-199???	154-210
154??-210??

217?-230	217???-230??	236-236??	239-239??	271-331	271??-331??	377-435
377??-435??

Modified residues / Rysidus modifiys / Residuos modificados

E

1-1?-1??-1???

 	pyroglutamic acid

acide pyroglutamique

acido piroglutamico

Glycosylation sites / Sites de glycosylation / Posiciones de
glicosilaciun

Asn-307	Asn-307??



Molecular formula	C6462H9942N1714O2036S46

Description

immunoglobulin G1, anti-[rabies virus glycoprotein], Homo sapiens
monoclonal antibody, CR57; gamma1 heavy chain (1-456) [Homo sapiens VH
(IGHV1-69-(IGHD)-IGHJ5*02) [8.8.20] (1-127) -IGHG1*03, CH3 K130>del
(128-456)], (230-217?)-disulfide with lambda light chain (1?-218?) [Homo
sapiens V-LAMBDA (IGLV2-11-IGLJ2*01) [9.3.12] (1?-112?) -IGLC2*01
(113?-218?)]; (236-236??:239-239??)-bisdisulfide dimer 

	

WHO 

International Nonproprietary Names Programme	

9052

1/1

		

